Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function

Poitiers University Hospital39 enrolled

Overview

The purpose of this study is to determine the pharmacokinetic profile of Revlimid® in patients presenting with Multiple Myeloma and impaired renal function, the safety of Revlimid® in the enrolled patients population. and evaluate the efficacy of Revlimid®-Dexamethasone combination in patients presenting MM and impaired renal function at completion of 3 cycles of treatment.

Study Type

INTERVENTIONAL

Enrollment

Conditions

Multiple Myeloma Impaired Renal Function

Interventions

lenalidomideDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Documented diagnosis of relapsed or refractory multiple myeloma (MM). * Age \> 18 years at the time of signing the informed consent form * Stable renal function Exclusion Criteria: * Documented amyloidosis * Any prior use of Revlimid ® * Any contraindication to Revlimid ® and especially: * Lack of acceptable method of birth control for female of childbearing potential (FCPB) * Men who don't agree to use condom during the study and 4 weeks after the last study drug intake if their partner is a FCPB. * Pregnant or breast feeding women

Locations (1)

Poitiers University Hospital

Poitiers, France

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.